Information about TRUVADA and ATRIPLA delisting

Australian Federation of AIDS Organisations (AFAO), March 30th 2020

From 1 April 2020 Truvada for HIV treatment and for pre-exposure prophylaxis (PrEP) will no longer be available through the Pharmaceutical Benefits Scheme (PBS).

There are alternatives to Truvada for PrEP in Australia.

Community members eligible for PrEP can access generic versions of Truvada supplied by Apotex, Mylan and Lupin Generic Health. The drugs manufactured by these three suppliers contain the same active ingredients as Truvada.

In addition, from October 2020 Atripla will be delisted. A generic equivalent of Atripla has been approved by the PBS for community members who wish to continue using Atripla.

We encourage you to talk to your prescribing doctor if you want more information about these changes.

For more information, visit the following websites:

HIV vaccine therapy lets five people control virus without drugs

New Scientist, 22 February 2017

FIVE people with HIV are currently free of detectable virus – and daily drugs – thanks to a new vaccine-based therapy.

Although it is early days, one participant has been drug-free for seven months.

Read  more here 

Anti-booze drug may flush out dormant HIV and could lead to cure

New Scientist, 16 November 2015

It could be just what HIV researchers the world over have been waiting for – a non-toxic drug that will drive the virus from its hiding places around the body. What is it? The well-known anti-alcohol drug, Antabuse.

Read more here

 

HIV Therapy May Also Lower Risk for Hepatitis B, Study Says

Medline Plus, October 12, 2015

Not only does effective HIV therapy thwart that virus, it may also reduce the risk for hepatitis B infection, a new study says.

“What this means to us is that effective HIV therapy appears to restore an impairment in the immune response that protects someone with HIV from acquiring hepatitis B infection,” study senior author Dr. Chloe Thio said.

Read more here

Australia’s biggest study on the use of HIV prevention treatment begins

Star Observer, 26 Nov 2014

If massively reducing your chances of contracting a chronic virus was as simple as regularly popping a pill, would you take your daily dose?

That’s the question researchers from the University of NSW’s Kirby Institute will be asking 300 HIV-negative men over the next two years.

  • Read more here
  • Find out more about the PrELUDE Study here